Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | short review

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders

verfasst von: Panagiotis D. Tsirigotis, M.D., Nikolaos Papanikolaou, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Natural killer (NK) cells are cytotoxic against a variety of transformed and virus-infected cells. Cytotoxicity of NK cells is regulated through complex interactions between receptors expressed on NK surface and their cognate ligands expressed on the surface of target cells. A large body of data supports the concept that NK are key players of immune surveillance against cancer, and NK cell based immunotherapy has been proved to be feasible and effective. Allogeneic NK cell infusion, in nontransplant recipients with malignant disorders, is associated with a modest but of a short-term duration antitumor effect. The major limitation of allogeneic-NK therapy is the inevitable rejection of allogeneic effectors and the termination of antitumor activity. Allogeneic NK cells are not rejected by the host if infused after stem cell transplantation from the same donor. Although the existing data are limited, allogeneic-NK immunotherapy is much more effective if performed after haploidentical stem cell transplantation. Future trials should address this issue.
Literatur
1.
Zurück zum Zitat Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995;7:704–10.CrossRefPubMed Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995;7:704–10.CrossRefPubMed
2.
Zurück zum Zitat Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:399–409.CrossRefPubMed Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:399–409.CrossRefPubMed
3.
Zurück zum Zitat Etzioni A, Eidenschenk C, Katz R, Beck R, Casanova JL, Pollack S. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr. 2005;146:423–5.CrossRefPubMed Etzioni A, Eidenschenk C, Katz R, Beck R, Casanova JL, Pollack S. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr. 2005;146:423–5.CrossRefPubMed
4.
5.
Zurück zum Zitat Tsirigotis PD, Resnick IB, Shapira MY. The role of natural killer cells in hematopoietic stem cell transplantation. Ann Med. 2012;44(2):130–45.CrossRefPubMed Tsirigotis PD, Resnick IB, Shapira MY. The role of natural killer cells in hematopoietic stem cell transplantation. Ann Med. 2012;44(2):130–45.CrossRefPubMed
6.
Zurück zum Zitat Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–92.CrossRefPubMed Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–92.CrossRefPubMed
7.
Zurück zum Zitat Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824–32.CrossRefPubMed Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824–32.CrossRefPubMed
8.
Zurück zum Zitat Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2005;11:181–7.CrossRef Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2005;11:181–7.CrossRef
9.
Zurück zum Zitat Torelli GF, Guarini A, Palmieri G, et al. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. Br J Haematol. 2002;116:299–307.PubMed Torelli GF, Guarini A, Palmieri G, et al. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. Br J Haematol. 2002;116:299–307.PubMed
10.
Zurück zum Zitat Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol. 2002;117(4):821–7.CrossRefPubMed Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol. 2002;117(4):821–7.CrossRefPubMed
11.
Zurück zum Zitat Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.CrossRefPubMed Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.CrossRefPubMed
12.
Zurück zum Zitat Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–9.PubMed Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–9.PubMed
13.
Zurück zum Zitat Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.CrossRefPubMed Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.CrossRefPubMed
14.
Zurück zum Zitat Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118:3273–9.CrossRefPubMed Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118:3273–9.CrossRefPubMed
15.
Zurück zum Zitat Cooley S, Foley B, Verneris MR, et al. Haploidentical natural killer (NK) cells expanding in vivo after adoptive transfer exhibit hyperfunction that partially overcomes self tolerance and leads to clearance of refractory leukemia. Blood. 2011;118 (Abstract 355). Cooley S, Foley B, Verneris MR, et al. Haploidentical natural killer (NK) cells expanding in vivo after adoptive transfer exhibit hyperfunction that partially overcomes self tolerance and leads to clearance of refractory leukemia. Blood. 2011;118 (Abstract 355).
16.
Zurück zum Zitat Slavin S, Ackerstein A, Or R, et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunol Immunother. 2010;59:1511–9.CrossRefPubMed Slavin S, Ackerstein A, Or R, et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunol Immunother. 2010;59:1511–9.CrossRefPubMed
17.
Zurück zum Zitat Slavin S, Or R, Aker M, et al. Treatment of resistant leukemia by rIL-2 activated NK cells in recipients of HLA matched and haploidentically mismatched stem cell allografts while avoiding GVHD. Blood. 2004;104:379 (Abstract 5180). Slavin S, Or R, Aker M, et al. Treatment of resistant leukemia by rIL-2 activated NK cells in recipients of HLA matched and haploidentically mismatched stem cell allografts while avoiding GVHD. Blood. 2004;104:379 (Abstract 5180).
18.
Zurück zum Zitat Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835–8.CrossRefPubMed Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835–8.CrossRefPubMed
19.
Zurück zum Zitat Koehl U, Sörensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261–6.CrossRefPubMed Koehl U, Sörensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261–6.CrossRefPubMed
20.
Zurück zum Zitat Laport G, Sheehan K, Baker J et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1679–87.CrossRefPubMed Laport G, Sheehan K, Baker J et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1679–87.CrossRefPubMed
Metadaten
Titel
Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders
verfasst von
Panagiotis D. Tsirigotis, M.D.
Nikolaos Papanikolaou, M.D.
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0010-7

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe